Use of nalbuphine and related compounds to treat symptoms of respiratory problems

• US 20080207667A1
• Filed: 02/23/2007
• Published: 08/28/2008
• Est. Priority Date: 02/23/2007
• Status: Abandoned Application

• Current Assignee: Robert W. Rhame
• Original Assignee: Robert W. Rhame
• Inventors: Rhame, Robert W.
• Application Number:
  US11/710,383
• Publication Number:
  US 20080207667A1
• Time in Patent Office: Days
• US Class Current: 514/282
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to treatment of respiratory diseases. More specifically, the present invention relates to treatment of respiratory diseases in humans and lower animals with nalbuphine.

Claims

1. A method of treatment of symptoms associated with diseases affecting the respiratory or pulmonary system of humans and lower animals, comprising administration to the human or lower animal safe and effective amounts of a composition including nalbuphine.

2. The method according to claim 1, wherein the symptoms associated with diseases affecting the respiratory system include one or more of asthma, cough, bronchoconstriction, cough with pruritis, chronic obstructive pulmonary disease, dyspnea, pulmonary hypertension, or pulmonary symptoms, and distress associated with cardiac disease or failure or cancerous processes involving the respiratory system.

3. The method according to claim 1, wherein the composition is administered by methods including one or more of topically, intranasally, orally, intravenously, intramuscularly, via the buccal mucosa, and subcutaneously.

4. The method according to claim 1, wherein the composition includes a salt of nalbuphine.

5. The method according to claim 4, wherein the salt of nalbuphine is nalbuphine hydrochloride.

6. The method according to claim 1, wherein the composition further includes one or more of antihistamines, decongestants, expectorants, bronchodilators, beta-2-agonists, opoid agonists, opoid antagonists, and antitussives.

7. The method according to claim 1, further comprising an excipient.

8. The method according to claim 1, further comprising one or both of a steroidal or nonsteroidal anti-inflammatory drug agent.

9. The method according to claim 1, further comprising an anticholinergic drug agent.

10. The method according to claim 1, wherein the composition is in the form of an aqueous solution.

11. The method according to claim 1, wherein the composition is nebulized.

12. The method according to claim 1, wherein the composition is aerosolized.

13. A combination comprising:

a container comprising a means for topical application selected from the group consisting of dropper means, spray means, and inhalation mist means, the container containing;

a composition for treatment of symptoms associated with respiratory diseases, in the form of an aqueous solution comprising a safe and effective amount of one or both of nalbuphine or a pharmaceutically acceptable salt thereof.

14. The combination according to claim 13, wherein the container further comprises a suitable excipient.

15. The combination according to claim 13, further comprising a drug agent selected from the group consisting of antihistamines, decongestants, expectorants, bronchodilators, beta-2-agonists, opoid agonists, opoid antagonists, and antitussives.

16. The combination according to claim 13, further comprising one or both of a steroidal and non-steroidal anti-inflammatory drug agent.

17. The combination according to claim 13, further comprising an anticholinergic drug agent.

18. A composition for treatment of symptoms associated with respiratory diseases, the composition comprising one or both of nalbuphine and a pharmaceutically acceptable salt thereof, and a safe and effective amount of another drug active selected from the group consisting of antihistamines, decongestants, expectorants, bronchodilators, beta-2-agonists, opoid agonists, opoid antagonists, antitussives, and combinations thereof.

19. The composition according to claim 18, wherein the composition is in the form of a tablet, an aqueous solution, or an inhalation mist.

20. The composition according to claim 18, further comprising a preservative.

21. The composition according to claim 18, further comprising a steroidal or non-steroidal anti-inflammatory drug agent.

22. The composition according to claim 18, further comprising an anticholinergic drug agent.